The UK pharma group fought Pfizer's $120 billion bid by promising growth. But its defence has been aided most by U.S. curbs on tax-driven M&A, says Reuters Breakingviews.
01:15
02:59
01:05
01:01
02:16
01:17
03:16
00:40
00:41
01:33
00:31
01:03
01:26
00:42
02:42
01:30
01:27
01:44
02:44
01:43
00:58
02:22
02:08
01:01
01:01
00:48
01:02
03:00
01:24
01:41
01:54
01:20
02:24
01:02
01:10
01:20
01:20
02:01
01:09
02:23
01:51
00:41
00:42
00:31
01:09
01:17
01:18
01:23
01:01
01:49
01:08
02:08
00:59
01:07
00:54
01:36
01:07
01:47
02:03
01:05
01:39
04:35
01:52
01:02
00:52
01:25
01:31
01:08
01:15
00:48
01:45
04:52
02:00
01:33
01:26
00:54
01:14
01:07
01:01
01:39
01:15
02:59
01:05
01:01
02:16
01:17
03:16
00:40
01:33
01:26
01:27
01:43
01:02
01:33
01:34
01:02
01:10
01:24
01:12
00:45
01:29
00:52
02:00
02:00
01:04
01:19
00:47
01:26
01:13
01:22
01:22
01:15
01:20
01:33
01:28
01:48
02:33
01:28
03:40
01:05